A prospective Study examining The contribution to Renal anemia treatment of ferric citrate hydrate, an Ironbased Oral phosphate binder, in hemodialysis patients with hyperphosphatemia : ASTRIO Study
Not Applicable
- Conditions
- Maintenance hemodialysis patients with hyperphosphatemia
- Registration Number
- JPRN-UMIN000019176
- Lead Sponsor
- Japan Tobacco Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have administrated of oral iron agents within 4weeks before entry. 2) Patients with uncontrolled serum P 3) Patients with uncontrolled serum Ca 4) Patients with uncontrolled serum Hb 5) Patients with uncontrolled hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in ESA dose from baseline to the end of treatment.
- Secondary Outcome Measures
Name Time Method 1) Cumulative dose of intravenous iron during the study. 2) Cumulative dose of ESA during the study. 3) ESA dose at each observation. 4) ERI at each observation. 5) Red blood cell related parameters at each observation. 6) Iron related parameters at each observation. 7) CKD-MBD related parameters at each observation.